Industry News
Excerpt from the Press Release: “WAKEFIELD, MA – July 20, 2020 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, reports today receiving new data from ongoing laboratory testing being conducted at a U.S. Regional Biocontainment Laboratory (RBL). The data is helping to inform the planned Phase 2 clinical trial of Brilacidin…
Read More
Excerpt from the Press Release: “BOSTON, July 20, 2020 (GLOBE NEWSWIRE) — Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the launch of an Expanded Access Program (EAP) for investigational lead product candidate odevixibat, a highly potent and selective inhibitor of the ileal bile…
Read More
Excerpt from the Press Release: “Alexandria, VA—The American Society of Clinical Oncology (ASCO) and Association of Community Cancer Centers (ACCC) today announced a new collaboration to foster participation in cancer treatment trials to more fully reflect the diversity of people at risk for or living with cancer. The joint ASCO-ACCC initiative is designed to identify…
Read More
Excerpt from the article: “Twelve days from the planned start of their Phase III pivotal trial, the executive crew at Moderna has set up the manufacturing base needed to begin production of the first 500,000 doses of their Covid-19 vaccine with plans to feed it into a global supply chain. But the initial batches will…
Read More
Excerpt from the Press Release “CAMBRIDGE, Mass.–(BUSINESS WIRE)–Oncorus, Inc., a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that it has initiated a Phase 1 study of its lead product candidate, ONCR-177, an intratumorally administered oncolytic Herpes Simplex Virus (oHSV) viral immunotherapy being developed for multiple solid tumor…
Read More
Excerpt from the Press Release: “SAN DIEGO, July 16, 2020 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced the initiation of the GUARDS-1 Study, a Phase 2 clinical study…
Read More
Excerpt from the press release: “SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Centivax Inc, the therapeutics spinout of Contract Research Organization Distributed Bio Inc, announced today that their antibody therapeutic protects hamsters from SARS-CoV-2, the COVID-19-causing coronavirus. Confirmed simultaneously at two independent national laboratories, these results provide critical support for the antibody to move to clinical studies to…
Read More
Excerpt from the article: “An aerosol-based drug treatment could drastically reduce the number of new coronavirus patients dying from the disease or requiring intensive care, according to preliminary results released by a British biotech firm. In a randomised trial of 100 patients admitted to hospital with COVID-19, those who received an inhaled formula of the…
Read More
Excerpt from the article: “GENEVA and SUNNYVALE, Calif., July 16, 2020 /PRNewswire/ — The Foundation for Innovative New Diagnostics (FIND) and Cepheid, Inc, announced today the launch of the new Xpert® MTB/XDR* test, which enables expanded drug-resistance tuberculosis (TB) profiling in less than 90 minutes. Xpert MTB/XDR can be used to empower clinicians to quickly prescribe…
Read More
Excerpt from the press release: MALVERN, Pa. & SAN DIEGO–(BUSINESS WIRE)–Jul. 16, 2020– PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that it has dosed the first patient in VANGARD, a potentially pivotal Phase 2 clinical trial to evaluate PB1046…
Read More